Navigation Links
Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
Date:5/15/2008

Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover

and Aspirin, According to a New Report from Decision Resources

WALTHAM, Mass., May 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Daiichi Sankyo/Eli Lilly's Effient offers improvement in patient compared to Sanofi-Aventis/Bristol Myers Squibb's Plavix/Iscover in the treatment of post-myocardial infarction. Effient and AstraZeneca's ticagrelor, which is in Phase III trials, are positioned to offer advantages over Plavix/Iscover such as quick onset of action, greater potency, consistent effect, and a quick offset of action. However, clinical trials demonstrate that Effient cause more major bleeding than Plavix/Iscover and that ticagrelor must be twice-daily dosed, in comparison with Plavix/Iscover's once-daily dose. The new ADP receptor antagonists Effient and ticagrelor will be launched in 2009 and 2011, respectively. However, with Plavix/Iscover's patent expiry in 2011, only modest patient shares are expected for the new agents because of the increased competitiveness of generic clopidogrel.

The new report entitled Post-Myocardial Infarction: Emerging Therapies Must Offer Physicians More Evidence to Prove Clear Benefits further finds that an unmet need exists for an antiplatelet therapy for post-myocardial infarction that is as effective as Plavix/Iscover but that, combined with aspirin, causes less major bleeding than the combination of Plavix/Iscover and aspirin. An agent of this type would earn 43 percent patient share in post-myocardial infarction, according to primary care physicians.

"Surveyed primary care physicians consider less bleeding an important safety attribute, and the results of our survey indicate that they are not satisfied with the level of bleeding caused by the combination of Plavix/Iscover and aspirin," said Jeremy Goldman, M.D., analyst at Decision Resources. "Because Plavix/Iscover is the only adenosine diphosphate receptor antagonist used in combination with aspirin (excluding the occasional use of ticlopidine [Roche/Sanofi-Aventis's Ticlid, Daiichi Sankyo's Panaldine, generics]) in the United States, there is considerable opportunity for an antiplatelet agent that is as effective as Plavix/Iscover when it is added to aspirin but does not bring the higher risk of major bleeding."

About the Report

Post-Myocardial Infarction: Emerging Therapies Must Offer Physicians More Evidence to Prove Clear Benefits is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com), is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
4. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
5. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
6. STAR Cranial Centers of Excellence Offer Cutting-Edge Treatment to Dallas Area Children
7. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
8. Clinically Proven Treatment Offers Help to Rosacea Sufferers
9. Arizona Doctor Offers New Addiction Drug Treatment for Meth Addicts Showing More Than 60% Success Rate
10. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
11. New York-Presbyterian/Weill Cornell is First New York Medical Center to Offer Tantalus Clinical Trial to Diabetes Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...  LivaNova, PLC, Hersteller des VNS-Therapie ® ... Titel „Epilepsy Around the World" (Epilepsie auf ... gegenüber ein größeres Bewusstsein gefördert werden soll ... Epilepsie auf dem Internationalen Epilepsietag zu einem ... der neuen Infografik sollen wichtige Statistiken zur ...
(Date:2/5/2016)... Calif. , Feb. 5, 2016  Syneron ... global aesthetic device company, announced today that ... Candela North America, is scheduled to participate in ... Healthcare Conference on February 11, 2016 in ... will allow institutional investors to meet with the ...
(Date:2/5/2016)... 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced ... ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of ... Tribute. The combined company will operate under Aralez Pharmaceuticals ... in Canada , Ireland ... . Under the terms of the Agreement and Plan ...
Breaking Medicine Technology:
(Date:2/5/2016)... FL (PRWEB) , ... February 05, 2016 , ... ... the largest domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual ... awareness for kids and adults with muscular dystrophy, ALS and related diseases that ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official operators of ... direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque ... , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each ... longer to access the treadmills. It’s a predictable trend. After the excesses of November ... get in shape by joining gyms, starting new walking or running routines, or signing ...
(Date:2/5/2016)... WA (PRWEB) , ... February 05, 2016 , ... ... firm, ranked #3 in the 2015 Best in KLAS: Software & Services for ... The annual Best in KLAS report independently ranks vendor performance by healthcare executives, ...
Breaking Medicine News(10 mins):